QUVIVIQ™ is indicated for the treatment of adult patients with insomnia, characterized by symptoms present for at least three months and considerable impact on daytime functioningQUVIVIQ,. | June 12, 2023
Idorsia Pharmaceuticals Ltd: Idorsia launches QUVIVIQ (daridorexant) in Switzerland - a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
QUVIVIQ is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioningQUVIVIQ, Switzerland's first